A Long Term Follow-up Study of TScan TCR-T Products
Launched by TSCAN THERAPEUTICS, INC. · May 13, 2025
Trial Information
Current as of July 21, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial, called the Long Term Follow-Up Study of TScan TCR-T Products, aims to keep a close eye on patients who have previously received special treatments known as TCR-T therapies (specifically TSC-100 or TSC-101) for blood cancers like acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and myelodysplastic syndromes (MDS). Over a period of 15 years, researchers will monitor the participants to learn more about the long-term safety and effectiveness of these therapies.
To be eligible for this study, participants need to have received TCR-T therapy in an earlier clinical trial sponsored by TScan Therapeutics and must sign a consent form to join. There are no specific exclusions, meaning that anyone who meets the inclusion criteria can participate. If you or a family member are eligible, you can expect to be part of a long-term follow-up that helps improve understanding of these innovative treatments and supports future advancements in care.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Participants who received a TCR-T cellular therapy in a clinical study sponsored by TScan Therapeutics.
- • Signed informed consent.
- Exclusion Criteria:
- • None
About Tscan Therapeutics, Inc.
Tscan Therapeutics, Inc. is a biotechnology company focused on advancing innovative T cell-based therapies for the treatment of cancer and other serious diseases. Leveraging its proprietary T cell receptor (TCR) discovery platform, Tscan aims to identify and develop novel therapeutics that harness the power of the immune system to target and eliminate cancer cells. With a commitment to transforming patient outcomes through precision medicine, Tscan Therapeutics is dedicated to conducting rigorous clinical trials that pave the way for effective and safe treatment options for patients in need.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Duarte, California, United States
New York, New York, United States
Patients applied
Trial Officials
Michelle Matzko, MD
Study Director
Medical Monitor
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported